The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 18, 2020
Filed:
Jan. 12, 2018
Applicant:
Thermalin Inc., Waban, MA (US);
Inventors:
Richard William Berenson, Waban, MA (US);
Bruce Frank, Indianapolis, IN (US);
Michael A. Weiss, Moreland Hills, OH (US);
Thomas Hattier, Cleveland Heights, OH (US);
Gregory Dubé, Littleton, MA (US);
Zhiqiang Chen, Cleveland, OH (US);
Assignee:
THERMALIN, INC., Waban, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); A61K 9/00 (2006.01); A61K 36/05 (2006.01); A61K 36/23 (2006.01); A61K 47/18 (2017.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/20 (2006.01); A61K 47/36 (2006.01); A61M 5/142 (2006.01); A61M 5/172 (2006.01); A61M 25/02 (2006.01); A61M 37/00 (2006.01); A61N 1/04 (2006.01); A61N 1/32 (2006.01); A61N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/28 (2013.01); A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 36/05 (2013.01); A61K 36/23 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/36 (2013.01); A61M 5/142 (2013.01); A61M 5/1723 (2013.01); A61M 25/02 (2013.01); A61M 37/0092 (2013.01); A61N 1/0448 (2013.01); A61N 1/327 (2013.01); A61N 7/00 (2013.01); A61M 2025/0253 (2013.01); A61M 2037/0007 (2013.01); A61M 2205/055 (2013.01); A61M 2205/35 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2230/201 (2013.01);
Abstract
The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.